Live
FierceBiotechGilead turns down chance to build on Assembly's phase 1-stage HBV antiviralFierceBiotechNovartis pays Synnovation $2B upfront for breast cancer program as rivals circleEndpoints NewsNovartis to pay $2B upfront to take next-gen PI3Kα inhibitor from SynnovationThermo FisherEU Clears Thermo Fisher's Multibillion-Dollar Clario Acquistion - marketscreener.comEndpoints NewsIdorsia looks for another CEO — again; Former Jazz exec makes a comebackEndpoints NewsGenentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trialWatersFoguth Wealth Management LLC. Purchases New Stake in Waters Corporation $WAT - MarketBeatThermo FisherConfluence Investment Management LLC Acquires 11,841 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeatIlluminaIllumina, Inc. $ILMN Shares Sold by CIBC Private Wealth Group LLC - MarketBeatThermo FisherArgent Capital Management LLC Increases Stock Position in Thermo Fisher Scientific Inc. $TMO - MarketBeatAgilentAgilent’s USCAP 2026 Pathology Updates Deepen Oncology Diagnostics Narrative - simplywall.stAgilentAIA Group Ltd Invests $2.48 Million in Agilent Technologies, Inc. $A - MarketBeat
Endpoints News Mar 20, 2026

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation

Original
Body unavailable. Use the original source.

Directory

59 All